SDSushmitha S. Durgam

Sushmitha S. Durgam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sushmitha S. Durgam has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Matthew C. Stewart

    Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, 2001 South Lincoln Avenue, Urbana, IL 61801, USA

    6 shared publications
  • Matthew Stewart

    Department of Veterinary Clinical Medicine University of Illinois Urbana Illinois USA

    5 shared publications
  • Allison A. Stewart

    Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, 1008 W Hazelwood Drive, Urbana, Illinois, 61802

    4 shared publications
  • Allison A. Stewart

    Department of Veterinary Clinical Medicine, University of Illinois, Urbana-Champaign, Illinois, USA

    4 shared publications
  • Zarah A. Belacic

    Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH

    4 shared publications
  • Allison Stewart

    Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois , Urbana, Illinois

    3 shared publications

Latest Publications

  • Open Access

    Equine bone marrow aspirate and bone marrow aspirate concentrate are enriched with interleukin-1 receptor antagonist protein

    by Sidney Long, Grigorios Maleas, Zarah A. Belacic, Vivian G. Quam, Sushmitha Durgam

    Objective: To analyze the cellular, growth factor, and cytokine composition of equine sternal bone marrow aspirate (BMA) and laboratory-centrifuged BMA concentrate (BMAC). Methods: This was an in vitro experimental study. Cellular composition, growth factors (IGF-I, VEGF, PDGF, TGF-β1), and cytokines (IL-6, IL-10, tumor necrosis factor-α (TNF-α), and IL-1 receptor antagonist protein [IL-1Ra]) were quantified using a standard automated hematology analyzer and ELISA methods, respectively, in donor-matched BMA, BMAC (in-house centrifugation protocol), whole blood, and platelet-rich plasma (E-PET; Pall Inc) prepared from 25 horses from 2016 through 2020. Results: Leukocytes, neutrophils, monocytes, lymphocytes, and thrombocytes were increased 4.1-, 3.4-, 4.6-, 4.4-, and 2.5-fold in BMAC compared to BMA, respectively. Interleukin-1 receptor antagonist protein of BMAC was increased 21-fold compared to BMA and increased 117-fold compared to gravity filtration system–based, leukocyte-rich platelet-rich plasma. Conclusions: Laboratory centrifugation enriches the cellular and IL-1Ra concentrations of equine BMAC compared to BMA, with no significant changes in IGF-I, VEGF, PDGF, TGF-β1, IL-6, IL-10, or TNF-α concentrations. Clinical Relevance: Equine BMA and BMAC are patient-side biologics enriched with anti-inflammatory IL-1Ra and support further evaluation of equine BMAC for musculoskeletal tissue healing.


  • Open Access

    Equine bone marrow MSC‐derived extracellular vesicles mitigate the inflammatory effects of interleukin‐1β on navicular tissues in vitro

    by Vivian G. Quam, Zarah A. Belacic, Sidney Long, Hilary C. Rice, Madhu S. Dhar, Sushmitha Durgam

    Background: Safe, efficacious therapy for treating degenerate deep digital flexor tendon (DDFT) and navicular bone fibrocartilage (NBF) in navicular horses is critically necessary. While archetypal orthobiologic therapies for navicular disease are used empirically, their safety and efficacy are unknown. Mesenchymal stem cell‐derived extracellular vesicles (EV) may overcome several limitations of current orthobiologic therapies.Objectives: To (1) characterise cytokine and growth factor profiles of equine bone marrow mesenchymal stem cell (BM‐MSC)‐derived extracellular vesicles (BM‐EV) and (2) evaluate the in vitro anti‐inflammatory and extracellular matrix (ECM) protective potentials of BM‐EV on DDFT and NBF explant co‐cultures in an IL‐1β inflammatory environment.Study design: In vitro experimental study.Methods: Cytokines (IL‐1β, IL‐6, IL‐10, IL‐1ra and TNF‐α) and growth factors (TGFβ1, VEGF, IGF1 and PDGF) in equine BM‐EV isolated via ultracentrifugation and precipitation methods were profiled. Forelimb DDFT and NBF explant co‐cultures from seven horses were exposed to media alone, or media containing 2 × 109 ± 0.1 × 109 particles/mL or 10 μg/mL BM‐EV (BM‐EV), 10 ng/mL interleukin‐1β (IL‐1β), or IL‐1β + BM‐EV for 48 h. Co‐culture media IL‐6, TNF‐α, MMP‐3, MMP‐13 concentrations and explant sulphated glycosaminoglycan (sGAG) content were quantified.Results: IL‐6, IGF1 and VEGF concentrations were 102.1 (37.61–256.2) and 182.3 (163.1–226.3), 72.3 (8–175.6) and 2.4 (0.1–2.6), 108.3 (38.3–709.1) and 211.4 (189.1–318.2) pg/mL per 2 × 109 ± 0.1 × 109 particles/mL or 10 μg/mL 10 μg of BM‐EV isolated via ultracentrifugation and precipitation methods, respectively. Co‐culture media MMP‐3 in BM‐EV‐ (p = 0.03) and BM‐EV + IL‐1β‐treated (p = 0.01) groups were significantly lower than the respective media and IL‐1β groups. DDFT explant sGAG content of BM‐EV (p = 0.003) and BM‐EV + IL‐1β groups were significantly higher compared with IL‐1β group.Main limitations: Specimen numbers are limited, in vitro model may not replicate clinical case conditions, lack of non‐MSC‐derived EV control group.Conclusions: Equine BM‐EV contains IL‐6 and growth factors, IGF1 and VEGF. The anti‐inflammatory and ECM protective potentials of BM‐EV were evident as increased IL‐6 and decreased MMP‐3 concentrations in the DDFT‐NBF explant co‐culture media. These results support further evaluation of BM‐EV as an acellular and ‘off‐the‐shelf’ intra‐bursal/intrasynovial therapy for navicular pathologies.


  • Open Access

    Interleukin-6 upregulates extracellular matrix gene expression and transforming growth factor β1 activity of tendon progenitor cells

    by Nadine Altmann, Charles Bowlby, Haley Coughlin, Zarah Belacic, Stasia Sullivan, Sushmitha Durgam

    Background: Prolonged inflammation during tendon healing and poor intrinsic healing capacity of tendon are causal factors associated with tendon structural and functional degeneration. Tendon cells, consisting of mature tenocytes and tendon progenitor cells (TPC) function to maintain tendon structure via extracellular matrix (ECM) synthesis. Tendon cells can succumb to tissue cytokine/chemokine alterations during healing and consequently contribute to tendon degeneration. Interleukin-(IL-)1β, IL-6 and TNFα are key cytokines upregulated in injured tendons; the specific effects of IL-6 on flexor tendon-derived TPC have not been discerned. Methods: Passage 3 equine superficial digital flexor tendon (SDFT)-derived TPC were isolated from 6 horses. IL-6 impact on the viability (MMT assay with 0, 1, 5 and 10 ng/mL concentrations), migration (scratch motility assay at 0, 10ng/mL concentration) of TPC in monolayer culture were assessed. IL-6 effect on tendon ECM and chondrogenic gene expression (qRT-PCR), TGFβ1 gene expression and activity (ELISA), and MMP-1, -3 and − 13 gene expression of TPC was evaluated. Results: IL-6 decreased TPC viability and migration. IL-6 treatment at 10 ng/mL significantly up-regulated TGFβ1 gene expression (6.3-fold; p = 0.01) in TPC, and significantly increased the TGFβ1 concentration in cell culture supernates. IL-6 (at 10 ng/mL) significantly up-regulated both tendon ECM (COL1A1:5.3-fold, COL3A1:5.4-fold, COMP 5.5-fold) and chondrogenic (COL2A1:3.9-fold, ACAN:6.2-fold, SOX9:4.8-fold) mRNA expression in TPC. Addition of SB431542, a TGFβ1 receptor inhibitor, to TPC in the presence of IL-6, attenuated the up-regulated tendon ECM and chondrogenic genes. Conclusion: IL-6 alters TPC phenotype during in vitro monolayer culture. Pro- and anti-inflammatory roles of IL-6 have been implicated on tendon healing. Our findings demonstrate that IL-6 induces TGFβ1 activity in TPC and affects the basal TPC phenotype (as evidenced via increased tendon ECM and chondrogenic gene expressions). Further investigation of this biological link may serve as a foundation for therapeutic strategies that modulate IL-6 to enhance tendon healing.


  • Open Access

    Macrophage phenotype impacts in vitro equine intrasynovial deep digital flexor tenocyte matrix metalloproteinase gene expression and secretion

    by Hannah E. Cooper, Charles Bowlby, Sidney Long, Sushmitha S. Durgam

    OBJECTIVE: To investigate matrix metalloproteinase (MMP) and their inhibitors tissue inhibitor matrix metalloproteinase (TIMP) gene expression and secretion during equine deep digital flexor tendon (DDFT) tenocyte and macrophage (undifferentiated, proinflammatory, and regulatory) co-culture. SAMPLE: Third passage DDF tenocytes and donor-matched macrophages differentiated from peripheral blood CD14+ monocytes from 5 healthy horses ages 9–11 years, euthanized for reasons unrelated to musculoskeletal conditions. METHODS: Passage 3 DDT tenocyte aggregate cultures were co-cultured with undifferentiated (control), proinflammatory (granulocyte-macrophage colony-stimulating factor; GM-CSF pretreated and lipopolysaccharide + interferon gamma-primed; LPS+IFN-γ) or regulatory (interleukin-4 and interleukin-10-primed; IL-4 + IL-10) macrophages in direct and transwell co-cultures for 72 hours. MMP-1, -2, -3, -9, -13, and TIMP -1, -2 mRNA were measured via real-time Polymerase Chain Reaction (rtPCR). Co-culture media MMP -3, -9, and TIMP -1, -2 concentrations were quantified via ELISA. RESULTS: Direct co-culture of DDF tenocytes with proinflammatory macrophages for 72 hours increased MMP-1, -3, and -13 mRNA levels whereas, MMP-9 mRNA levels decreased. Direct and transwell co-culture with proinflammatory and regulatory macrophages resulted in increased MMP-3 and decreased MMP-9 media concentrations. While direct co-culture with regulatory macrophages significantly increased TIMP-1 mRNA, overall, TIMP mRNA and culture media concentrations were largely unchanged. CLINICAL RELEVANCE: Cell-to-cell contact between DDF tenocytes and macrophages is not essential to induce MMP gene expression and secretion. Co-culture systems offer a viable in vitro platform to screen and evaluate immunomodulatory properties of therapies aimed at improving equine intrasynovial tendon healing.


  • Open Access

    Interleukin-1β and methylprednisolone acetate demonstrate differential effects on equine deep digital flexor tendon and navicular bone fibrocartilage cells in vitro

    by Zarah A. Belacic, Stasia N. Sullivan, Hilary C. Rice, Sushmitha S. Durgam

    OBJECTIVE: To investigate the effects of interleukin-1β (IL-1β) and methylprednisolone acetate (MPA) on equine intrabursal deep digital flexor tendon (DDFT) and navicular bone fibrocartilage (NBF) cells in vitro. SAMPLE: Third passage DDFT and NBF cells from 5 healthy donor horses ages 11–17 years euthanized for reasons unrelated to musculoskeletal conditions. PROCEDURES: Aggregate cultures were incubated with culture medium alone (control), 10 ng/mL IL-1β, 10 ng/mL IL-1β + 0.05 mg/mL MPA, or 10 ng/mL IL-1β + 0.5 mg/mL MPA for 24 hours. Extracellular matrix (ECM) gene expressions were assessed via real-time polymerase chain reaction (rtPCR). Culture media matrix metalloproteinase (MMP) -3 and -13 concentrations were quantified via ELISA. Total glycosaminoglycan (GAG) content in the cell pellets and culture media was also assessed. RESULTS: IL-1β and IL-1β combined with MPA significantly downregulated ECM gene expression to a greater extent in NBF cells compared with DDFT cells. IL-1β and IL-1β combined with MPA significantly upregulated MMP-3 culture media concentrations in DDFT cells only, and MMP-13 culture media concentrations to a greater extent in NBF cells compared with DDFT cells. CLINICAL RELEVANCE: NBF cells were more susceptible to IL-1β and MPA-mediated ECM gene expression downregulation in vitro. These results serve as a first step for future work to determine intrabursal corticosteroid regimens that limits or resolve the inflammation as well as take into consideration NBF cell biosynthesis in horses with navicular disease, for which currently no information exists.


  • Autologous platelet-rich plasma effects on Staphylococcus aureus–induced chondrocyte death in an in vitro bovine septic arthritis model

    by Andrew J.T. Muir, Andrew J. Niehaus, Joseph W. Lozier, Sara L. Cole, Zarah A. Belacic, Gregory A. Ballash, Sushmitha S. Durgam

    OBJECTIVE: To investigate the chondroprotective effects of autologous platelet-rich plasma (PRP), ampicillin-sulbactam (AmpS), or PRP combined with AmpS (PRP+AmpS) in an in vitro chondrocyte explant model of bovine Staphylococcus aureus–induced septic arthritis. SAMPLE: Autologous PRP and cartilage explants obtained from 6 healthy, adult, nonlactating Jersey-crossbred cows. ProcedureS: Autologous PRP was prepared prior to euthanasia using an optimized double centrifugation protocol. Cartilage explants collected from grossly normal stifle joints were incubated in synovial fluid (SF) alone, S aureus–inoculated SF (SA), or SA supplemented with PRP (25% culture medium volume), AmpS (2 mg/mL), or both PRP (25% culture medium volume) and AmpS (2 mg/mL; PRP+AmpS) for 24 hours. The metabolic activity, percentage of dead cells, and glycosaminoglycan content of cartilage explants were measured with a resazurin-based assay, live-dead cell staining, and dimethylmethylene blue assay, respectively. Treatment effects were assessed relative to the findings for cartilage explants incubated in SF alone. RESULTS: Application of PRP, AmpS, and PRP+AmpS treatments significantly reduced S aureus–induced chondrocyte death (ie, increased metabolic activity and cell viability staining) in cartilage explants, compared with untreated controls. There were no significant differences in chondrocyte death among explants treated with PRP, AmpS, or PRP+AmpS. CLINICAL RELEVANCE: In this in vitro explant model of S aureus–induced septic arthritis, PRP, AmpS, and PRP+AmpS treatments mitigated chondrocyte death. Additional work to confirm the efficacy of PRP with bacteria commonly associated with clinical septic arthritis in cattle as well as in vivo evaluation is warranted.


  • Open Access

    Zonal characterization and differential trilineage potentials of equine intrasynovial deep digital flexor tendon-derived cells

    by Vivian G. Quam, Nadine N. Altmann, Matthew T. Brokken, Sushmitha S. Durgam

    Background: Intrasynovial deep digital flexor tendon (DDFT) injuries occur frequently and are often implicated in cases of navicular disease with poor outcomes and reinjuries. Cell-based approaches to tendon healing are gaining traction in veterinary medicine and ultimately may contribute to improved DDFT healing in horses. However, a better understanding of the innate cellular characteristics of equine DDFT is necessary for developing improved therapeutic strategies. Additionally, fibrocartilaginous, intrasynovial tendons like the DDFT are common sites of injury and share a poor prognosis across species, offering translational applications of this research. The objective of this study is to isolate and characterize tendon-derived cells (TDC) from intrasynovial DDFT harvested from within the equine forelimb podotrochlear bursa. TDC from the fibrocartilaginous and tendinous zones are separately isolated and assessed. Flow cytometry is performed for mesenchymal stem cell (MSC) surface markers (CD 29, CD 44, CD 90). Basal tenogenic, osteogenic and chondrogenic markers are assessed via quantitative real time-PCR, and standard trilineage differentiation is performed with third passage TDC from the fibrocartilaginous (fTDC) and tendinous (tTDC) zones of DDFT. Results: Low-density plating isolated homogenous TDC populations from both zones. During monolayer passage, both TDC subpopulations exhibited clonogenicity, high in vitro proliferation rate, and fibroblast-like morphology. fTDC and tTDC were positive for MSC surface markers CD90 and CD29 and negative for CD44. There were no significant differences in basal tenogenic, osteogenic or chondrogenic marker expression between zones. While fTDC were largely restricted to chondrogenic differentiation, tTDC underwent osteogenic and chondrogenic differentiation. Both TDC subpopulations displayed weak adipogenic differentiation potentials. Conclusions: TDC at the level of the podotrochlear bursa, that potentially could be targeted for enhancing DDFT injury healing in horses were identified and characterized. Pending further investigation, promoting chondrogenic properties in cells administered exogenously into the intrasynovial space may be beneficial for intrasynovial tendon regeneration.